Liquidia Technologies has announced the appointment of former Teva Pharmaceuticals Global Head of Specialty Clinical Development Tushar Shah as the company’s first Chief Medical Officer. Prior to his most recent position, Shah had served as Senior VP, Global Respiratory Research and Development at Teva. His career in pharmaceutical research has also included positions as Senior VP, Scientific and Clinical Development at Altana Pharma US and US Head, Respiratory and Inflammation, Discovery Medicine and Clinical Pharmacology at GSK.
In April 2020, Liquidia announced that the FDA had accepted its NDA for its lead candidate, LIQ861 treprostinil DPI for the treatment of pulmonary arterial hypertension (PAH). LIQ861 is based on the company’s PRINT particle engineering technology. In June 2019, Liquidia announced that it had modified a deal with GSK giving Liquidia development and commercialization rights to several inhalation products manufactured with the PRINT technology.
Liquidia CEO Neal Fowler said, “Dr. Shah has had a long and distinguished career with nearly three decades of successful clinical development experience in high-profile therapeutic areas such as respiratory, immunology and neurology. His extensive leadership in this area comes at a pivotal moment in our company’s history with the LIQ861 NDA under review, LIQ865 in clinical development and a growing list of PRINT-derived preclinical candidates. Dr. Shah shares our passion for improving patients’ lives and I am confident that this addition to our outstanding management team moves us closer to achieving our mission.”
Shah commented, “I have dedicated my career to advancing strong science through the rigors of clinical development and regulatory approval with the goal of delivering meaningful benefit to patients in need. Liquidia is pioneering new ways to make good science better to achieve this objective. Using PRINT technology, we can specifically engineer therapies with the expressed goal of avoiding technical obstacles that stand in the way of addressing patient needs. This endeavor excites me, both professionally and intellectually, and I look forward to joining this incredibly talented team during a truly exciting and defining period for the company.”
Read the Liquidia Technologies press release.
